New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:15 EDTMGNXMacroGenics initiates Phase 1 study of MGD006
MacroGenics announced that a first patient received drug in a Phase 1 study of MGD006 in relapsed or refractory acute myeloid leukemia. MGD006 is a humanized, Dual-Affinity Re-Targeting, or DART, bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. This study marks the first clinical trial of a DART product candidate.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
12:13 EDTMGNXMacroGenics to host research and development day
Subscribe for More Information
07:23 EDTMGNXAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
09:15 EDTMGNXMacroGenics has reached 'intriguing entry point,' says Roth Capital
Noting that MacroGenics' stock has tumbled nearly 40% over the past three months, Roth Capital says that the decline has significantly discounted the differentiation of the company's cancer treatment, MGA271, and offers an intriguing entry point for long-term investors focused on MacroGenics' DART-platform. Roth keeps a $45 price target and Buy rating on the shares.
October 1, 2015
07:31 EDTMGNXLeerink to hold a roundtable
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use